Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03809234 · ClinicalTrials.gov registry record · Phase 1
Pgp Transporter and CNS Biodistribution of Ondansetron in Healthy Volunteers
A Phase 1 study, sponsored by Washington University School of Medicine.
- Terminated
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
NCT03809234: Clinical Trial Phase 1 study, sponsored by Washington University School of Medicine.
NCT03809234 is a Phase 1 study that was terminated before completion, run by Washington University School of Medicine. The registered enrollment target is 14 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (77% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03809234, a Phase 1 study, was terminated before completion, sponsored by Washington University School of Medicine.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
Study Summary
To determine the time-course of plasma and CSF concentrations of intravenous (IV) ondansetron in healthy subjects, with and without selective inhibition of Pgp efflux transporter.
Primary Outcome
CSF penetration of intravenous ondansetron will be determined as AUCCSF0-∞ of ondansetron, and compared between the two sessions, with and without tariquidar
Interventions
- DRUG Ondansetron 8mg with Saline & Tariquidar
- DRUG Ondansetron 16mg with Saline & Tariquidar
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2019-05-20 |
| Est. Completion | 2020-11-30 |
| Phase | Phase 1 |
Why NCT03809234 stopped before completion
NCT03809234 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (77% lower).
The record links to 0 conditions, and to 2 interventions - of which Ondansetron 8mg with Saline & Tariquidar is the first listed.
NCT03809234 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03809234 about?
NCT03809234 is a clinical study titled "Pgp Transporter and CNS Biodistribution of Ondansetron in Healthy Volunteers". To determine the time-course of plasma and CSF concentrations of intravenous (IV) ondansetron in healthy subjects, with and without selective inhibition of Pgp efflux transporter.
What is the current status of trial NCT03809234?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2019-05-20. Estimated completion is 2020-11-30.
What interventions are being tested in trial NCT03809234?
The interventions under investigation include: Ondansetron 8mg with Saline & Tariquidar (DRUG), Ondansetron 16mg with Saline & Tariquidar (DRUG).
Who is sponsoring clinical trial NCT03809234?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03809234's enrollment target sits among peer trials
14 1844th of 2000 higher than 154 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy